GLP1R and obesity due to melanocortin 4 receptor deficiency: With the recent development of agonists targeting GLP‐1 and GIP receptors for the treatment of type 2 diabetes and obesity, and the ongoing development of new incretin‐based drugs with improved efficacy, there is great interest in understanding the physiology and pharmacology of these hormones.